Johnson Investment Counsel Inc. Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Johnson Investment Counsel Inc. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,570 shares of the company’s stock after acquiring an additional 160 shares during the period. Johnson Investment Counsel Inc.’s holdings in Medpace were worth $522,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of MEDP. R Squared Ltd acquired a new stake in Medpace in the fourth quarter valued at $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace in the fourth quarter valued at $31,000. Stone House Investment Management LLC acquired a new stake in Medpace in the third quarter valued at $33,000. Ashton Thomas Securities LLC acquired a new stake in Medpace in the third quarter valued at $37,000. Finally, Jones Financial Companies Lllp raised its stake in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after buying an additional 110 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Down 0.3 %

NASDAQ MEDP opened at $324.91 on Thursday. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The business’s 50-day moving average price is $340.91 and its 200 day moving average price is $342.00. The firm has a market cap of $9.90 billion, a P/E ratio of 25.73, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.